Τhe development of chemotherapy for advanced Hodgkin lymphoma

Journal Title: Αρχεία Ελληνικής Ιατρικής - Year 2013, Vol 30, Issue 6

Abstract

During the past 50 years the treatment of Hodgkin lymphoma (HL) has pioneered the field of chemotherapy in oncology. Today more than 90% of patients with early stage HL and 80−85% of those with advanced disease can be ultimately cured with either first-line or salvage therapy. In 1964 de Vita and colleagues introduced the MOPP regimen that resulted in a long-term overall survival rate of 50%. In 1975 Βοnadonna and colleagues established the ABVD regimen, which is considered nowadays to be the standard of care with which other regimes should be compared. ABVD, alternating MOPP/ABVD, and MOPP/ABV hybrid were shown to be associated with a long-term survival rate of 70%, with a significant proportion of patients experiencing primary refractory or relapsing disease. In the 1990s, the German Hodgkin Study Group (GHSG) developed the BEACOPP-escalated regimen, which proved to be superior to COPP/ABVD in terms of freedom from treatment failure and overall survival in the HD9 trial. This outcome, however, was accomplished at the expense of significant hematological toxicity, toxic deaths and secondary neoplasms. The subsequent studies conducted by GHSG, HD12 and HD15 have established BEACOPP-escalated as a highly effective therapeutic option for patients aged up to 60 years, showing that 6 cycles were adequately therapeutic and less toxic than the originally administered 8 cycles. Two recently published Italian studies and the #20012 EORTC trial suggest, however, that BEACOPP-escalated may be no superior to ABVD in terms of overall survival. In conclusion, intensification of chemotherapy does not appear to be a panacea in the treatment of advanced HL; recognition of the subset of patients that would benefit from such an approach remains crucial to effective treatment.

Authors and Affiliations

A. KANELLOPOULOS, T. VASSILAKOPOULOS, J. MELETIS

Keywords

Related Articles

Telecardiology and its clinical applications

The success of any new telemedicine application depends on a large number of sensitive factors, including cost-effectiveness, efficacy, patient satisfaction, the related doctor-patient communication, and clinical outcome...

Flank approach adrenalectomy. A diachronic procedure

OBJECTIVE The surgical approach to the adrenal glands is always a matter of concern. Although laparoscopy is becoming ever more popular, the open approaches have specific indications. The flank approach for adrenalectomy...

Extrapancreatic effects of glucagon-like peptide-1

 Glucagon-like peptide-1 (GLP-1) is considered to be the most important of the incretin hormones (incretins), which are gastrointestinal hormones that are secreted after meals and reduce postprandial hyperglycemia....

Download PDF file
  • EP ID EP146818
  • DOI -
  • Views 98
  • Downloads 0

How To Cite

A. KANELLOPOULOS, T. VASSILAKOPOULOS, J. MELETIS (2013). Τhe development of chemotherapy for advanced Hodgkin lymphoma. Αρχεία Ελληνικής Ιατρικής, 30(6), 647-658. https://www.europub.co.uk/articles/-A-146818